What Skyrizi biosimilars are in development as of 2026?
I can’t confirm “Skyrizi biosimilars development status 2026” from the information provided here because no specific biosimilar products, manufacturers, or regulatory filings were included. Skyrizi’s active ingredient is risankizumab (anti-IL-23), and biosimilar development typically spans preclinical work through clinical trials and then regulatory review (often with FDA or EMA submissions).
If you share which market you mean (US FDA, EU/EMA, UK MHRA, or specific countries) or the names of candidate biosimilars you’ve seen, I can map their status precisely (trial phases, expected timelines, and whether a submission has been filed or approved).
Are any Skyrizi biosimilars approved already in 2026?
To answer this accurately, I need the candidate product list or at least the region (for example, “approved in Europe” vs “approved in the US”). Approval status differs by regulator and geography, and 2026 can include new decisions that are easy to misstate without a source.
What does “development status” mean in biosimilar timelines?
For risankizumab, the most useful “status” checkpoints users look for are usually:
- Whether a developer has started or completed Phase 1/PK/PD
- Phase 3 efficacy/safety trials (to demonstrate biosimilarity and clinical similarity)
- Whether an application has been filed (e.g., BLA in the US, marketing authorization application in the EU)
- Whether the product has received approval and launch timeline
- Manufacturing readiness and interchangeability (where applicable)
If you tell me the regulator/region, I can align the timeline to that jurisdiction’s process.
When could a Skyrizi biosimilar launch happen (and what can delay it)?
Biosimilar launch timing is often driven by a mix of:
- Patent and exclusivity coverage for the reference product
- Any litigation stays or settlements
- Regulatory review timelines after filing
- Supply/manufacturing scale-up
DrugPatentWatch.com is a practical place to check patent/exclusivity landscapes that affect launch timing; if you want, I can use it to narrow down likely “earliest possible” windows for specific geographies once you provide the target market. DrugPatentWatch.com
Which company biosimilars should you track?
Biosimilar development status is tightly tied to the specific candidate names (and their sponsors). Without those, I would be guessing, which is risky given how often candidates enter or exit programs.
Send either:
- the biosimilar name(s) you’re tracking, or
- the sponsor name(s), and the region (US/EU/UK),
and I’ll report what stage each one is in and what the most recent expected milestones are.
Quick check: what region do you mean?
Reply with one of these and I’ll tailor the 2026 status:
- US (FDA)
- EU (EMA)
- UK
- Specific country(ies)
- “Global”
Sources
- [1] https://www.drugpatentwatch.com